In this study, we aim to determine whether initiating intensive treatment early is beneficial for individuals newly diagnosed with psoriatic arthritis. One group begins treatment with an intensive therapy called secukinumab, which blocks IL-17. The other group starts with standard care using methotrexate. Both groups followed a “treat-to-target” approach, meaning their treatment was adjusted until minimal disease activity was achieved. After one year, both groups had similar results, but those who started intensive treatment felt better faster (within 3 months) and needed fewer medication switches. These findings suggest that early intensive treatment may help some patients feel better sooner and stay on treatment longer.